Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CPIXthis companyCumberland Pharmaceuticals Inc.	$5.30	-20.95×	2.39×	1.34×	19.7×	-102.6%	85.0%	-6.3%	-6.4%	-11.4%	-6.9%	8.1%	0.41×	-0.43×	-5.63×	1.01×	0.0%	3	0.04	2	C
ABVCABVC BioPharma, Inc.	$0.97	-5.46×	4.46×	0×	-7.04×	-109.1%	0.0%	0.0%	0.0%	-71.2%	-42.6%	-6.0%	0.31×	-0.38×	-17.2×	0.41×	0.0%	1	-5.28	1	C-
CALCCalciMedica, Inc.	$1.43	-3.35×	-14,896.04×	0×	-3,521.14×	-100.0%	0.0%	0.0%	0.0%	445.1%	-209.1%	-0.0%	-1.46×	0.06×	-16.26×	3.58×	0.0%	3	-15.99	1	C-
CELUCelularity Inc.	$0.76	-0.31×	-0.75×	1.07×	-0.81×	-1859.9%	24.4%	-230.9%	-345.4%	241.0%	-151.1%	-46.6%	-1.07×	-0.45×	-9.08×	0.15×	20.8%	3	-16.24	2	C
DYAIDyadic International, Inc.	$0.39	-4.09×	24.88×	24.89×	-4.53×	-156.5%	-88.3%	-579.9%	-597.6%	-597.6%	-113.6%	-18.6%	4.11×	-0.06×	-15.67×	2.68×	0.0%	3	-22.52	2	C
LTRNLantern Pharma Inc.	$0.57	-1.93×	5.05×	0×	-6.26×	-1222.3%	0.0%	0.0%	0.0%	-262.0%	-21.1%	-47.5%	12.02×	-4.33×	0×	2.4×	0.0%	1	-22.94	2	C+
Peer median	—	-3.35×	4.46×	0×	-6.26×	-156.5%	0.0%	0.0%	0.0%	-71.2%	-113.6%	-18.6%	0.31×	-0.38×	-15.67×	2.4×	0.0%	3	-16.24	2	—